Datopotamab Deruxtecan trials for Non-Small-Cell Lung Cancer

All Datopotamab Deruxtecan trials · All Non-Small-Cell Lung Cancer trials

Phase breakdown

Recruiting trials studying Datopotamab Deruxtecan for Non-Small-Cell Lung Cancer

• A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
  NCT06822543 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
  NCT06350097 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 167 locations
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
  NCT06357533 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 287 locations

Common questions

How many trials study Datopotamab Deruxtecan for Non-Small-Cell Lung Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.